8.—(1) At any meeting of an ethics committee, the committee may co-opt up to 2 additional members for the purposes of that meeting.U.K.
(2) At any meeting of a sub-committee of an ethics committee, the sub-committee may co-opt an additional member for the purposes of that meeting.
(3) Subject to sub-paragraph (4), a person shall be eligible to be co-opted as a member only if he is or has been a member of [F1a committee that advises or has advised on the ethics of research involving human subjects].
(4) [F2Sub-paragraph (3)] shall not apply in relation to the Gene Therapy Advisory Committee.
[F3(5) A co-opted member shall hold and vacate office in accordance with the ethics committee’s standing orders and operating procedures adopted under paragraph 6(3).]
(6) A member co-opted under this paragraph shall not count as a member for the purposes of paragraphs 3(2) and [F4(5)].
Textual Amendments
F1Words in Sch. 2 para. 8(3) substituted (1.5.2008) by The Medicines for Human Use (Clinical Trials) and Blood Safety and Quality (Amendment) Regulations 2008 (S.I. 2008/941), regs. 1(1), 5(6)(a)
F2Words in Sch. 2 para. 8(4) substituted (19.8.2010) by The Medicines for Human Use (Advanced Therapy Medicinal Products and Miscellaneous Amendments) Regulations 2010 (S.I. 2010/1882), regs. 1(1), 9(4)
F3Sch. 2 para. 8(5) substituted (1.5.2008) by The Medicines for Human Use (Clinical Trials) and Blood Safety and Quality (Amendment) Regulations 2008 (S.I. 2008/941), regs. 1(1), 5(6)(b)
F4Word in Sch. 2 para. 8(6) substituted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 28(c)